Clinical Research Directory
Browse clinical research sites, groups, and studies.
Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients
Sponsor: University of Wisconsin, Madison
Summary
This study is designed to assess how effective letermovir is in preventing recurrence of cytomegalovirus (CMV) infection in adult kidney or kidney/pancreas transplant recipients who are UW Health patients. Participants will be in the study for about 6 months.
Official title: An Interventional Study of Letermovir for Secondary Prophylaxis After Treatment of Cytomegalovirus Infection in High Risk (D+/R-) Kidney and Kidney/Pancreas Transplant Recipients
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
90
Start Date
2024-08-08
Completion Date
2026-09
Last Updated
2025-10-08
Healthy Volunteers
No
Interventions
Letermovir
480 mg taken orally once daily, for 84 days
Locations (1)
UW Hospital and Clinics
Madison, Wisconsin, United States